Tirzepatide and blood sugar

What sources report

How it acts on blood sugar

• Insulin and glucagon: tirzepatide boosts first- and second-phase insulin release and lowers glucagon, both only when glucose is raised.⁶ After 28 weeks, 15 mg cut fasting glucagon by 28% and after-meal glucagon by 43%, with no change on placebo.⁷
• Insulin sensitivity: in a clamp study in people with type 2 diabetes, insulin sensitivity improved after 28 weeks of treatment.⁸
• Drug class: MedlinePlus places it among the incretin mimetics, which help the pancreas release the right amount of insulin when blood sugar is high.⁹
• Two receptors: it acts on both the GIP and GLP-1 receptors, the targets of two gut hormones.¹⁰ In cell studies it bound the GIP receptor about as strongly as natural GIP.¹¹

Trials at a glance

SURPASS-1: tirzepatide on its own

SURPASS-1 compared tirzepatide 5, 10 or 15 mg with placebo for 40 weeks.¹²² Its 478 adults had diabetes not controlled by diet and exercise.¹² HbA1c fell 1.87%, 1.89% and 2.07% on the three doses (20, 21 and 23 mmol/mol), versus a 0.04% rise on placebo.² Body weight fell 7.0 to 9.5 kg.¹⁹ No clinically significant (below 54 mg/dL) or severe low blood sugar was reported with tirzepatide.²⁰

SURPASS-2: against semaglutide

SURPASS-2 added tirzepatide or semaglutide 1 mg to metformin in 1,879 adults for 40 weeks.¹³³ HbA1c fell 2.01, 2.24 and 2.30 percentage points with 5, 10 and 15 mg of tirzepatide, versus 1.86 with semaglutide.³ Every tirzepatide dose was noninferior and superior to semaglutide, and weight loss was 1.9 to 5.5 kg greater.²¹ Nausea occurred in 17% to 22% on tirzepatide versus 18% on semaglutide.²²

Children and teens

SURPASS-PEDS enrolled 99 patients aged 10 and older with type 2 diabetes.¹⁴ The 30-week randomized trial had a 22-week open-label extension.¹⁴ Both 5 mg and 10 mg once weekly lowered HbA1c significantly more than placebo.¹⁵ This trial supports the pediatric use added to the Mounjaro label in December 2025.¹⁴²³

Preventing type 2 diabetes

Among 1,032 adults with obesity and prediabetes in SURMOUNT-1, about 3 years of treatment led to 1.3% being diagnosed with type 2 diabetes, versus 13.3% on placebo.⁴⁵ The hazard ratio was 0.07.⁵ Diabetes prevention is not one of the labeled uses.¹²⁴ Weight results from the same trial are on Tirzepatide and weight loss.

A model estimate for the starting dose

The Mounjaro label includes an exposure-response analysis built from phase 2 and phase 3 data.²⁵ For 2.5 mg weekly, it projects an HbA1c drop of about 1.8% and a fasting glucose drop of about 43 mg/dL at 52 weeks.²⁵ That is a projection rather than a measured result, and the label still treats 2.5 mg as the starting step.²⁵²⁶

Heart outcomes

SURPASS-CVOT compared tirzepatide (up to 15 mg) with dulaglutide 1.5 mg in 13,299 adults with type 2 diabetes and established cardiovascular disease.¹⁶ Over a median of 210 weeks, 12.2% of people on tirzepatide and 13.1% on dulaglutide had a major cardiovascular event, a hazard ratio of 0.92.¹⁸¹⁷ That met the test for noninferiority, not for superiority.¹⁸ FDA added a heart risk indication to the Mounjaro label in August 2026.²⁷²³

What the label says

• Approved uses: Mounjaro is approved, with diet and exercise, to improve blood sugar control in adults and children 10 and older with type 2 diabetes.¹ It is also approved to lower the risk of cardiovascular death, heart attack or stroke in high-risk adults with type 2 diabetes.²⁷
• Dosing: it starts at 2.5 mg once weekly.²⁶ If more control is needed, the dose can rise by 2.5 mg once the current dose has been taken for at least 4 weeks.²⁶ The ceiling is 15 mg in adults and 10 mg in children.²⁸ The prescriber sets the dose; see Tirzepatide dosage.
• Who should not use it: people with a personal or family history of medullary thyroid carcinoma or MEN 2, or a known serious allergy to tirzepatide.²⁹
• Low blood sugar: the risk, including severe low blood sugar, rises when it is combined with insulin or a sulfonylurea.³⁰
• Stomach and bowel effects: in the diabetes trials they affected 37% to 44% on tirzepatide versus 20% on placebo, with nausea in 12% to 18% versus 4%.³¹³² Most nausea, vomiting and diarrhea occurred while the dose was being raised.³³
• Pancreatitis: confirmed cases occurred in 0.23 patients per 100 years of exposure, versus 0.11 on comparators.³⁴
• Eyes: rapid improvement in blood sugar has been linked to temporary worsening of diabetic retinopathy.³⁵ People with a history of it should be monitored.³⁵
• Not recommended: in severe gastroparesis.³⁶ Safety and effectiveness are not established under age 10.³⁷
• European Union: Mounjaro is used with diet and physical activity for type 2 diabetes in adults, adolescents and children 10 and older.³⁸

The brand page is What is Mounjaro?, and its goal page is Mounjaro and blood sugar. Side effects seen in the diabetes trials are on Tirzepatide side effects.

Research-labeled tirzepatide

The results on this page come from trials of the approved injectable. No FDA application covers research-labeled tirzepatide.³⁹ FDA warns that research-labeled GLP-1 products reaching consumers are of unknown quality, so none of these glucose results should be read as applying to them.⁴⁰

Other compounds studied for blood sugar are mapped on Peptides and blood sugar. The full compound profile is What is Tirzepatide?.